Search

Amgen Inc

Slēgts

SektorsVeselības aprūpe

410.09 4.33

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

379.52

Max

394.43

Galvenie mērījumi

By Trading Economics

Ienākumi

-3.6B

-1.8B

Pārdošana

1.4B

10B

P/E

Sektora vidējais

23.681

56.432

EPS

6.29

Dividenžu ienesīgums

2.6

Peļņas marža

-18.092

Darbinieki

31,500

EBITDA

-416M

3.4B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+3.39% upside

Dividendes

By Acuity

Dividenžu ienesīgums

Sektora vidējais

2.60%

2.27%

Nākamie ieņēmumi

2026. g. 3. nov.

Nākamais dividenžu datums

2026. g. 11. dec.

Nākamais Ex dividenžu datums

2026. g. 20. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

1.8B

206B

Iepriekšējā atvēršanas cena

405.76

Iepriekšējā slēgšanas cena

410.09

Ziņu noskaņojums

By Acuity

53%

47%

247 / 339 Rangs Healthcare

Amgen Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 18. sept. 20:06 UTC

Amgen Inc is trading higher on Friday, having advanced since Thursday's close, despite pulling back from an earlier session peak.

2026. g. 17. sept. 19:46 UTC

Macro Event

Amgen Inc is trading modestly higher, despite earlier fluctuations and remaining below its 20-day moving average amid a decline in U.S. jobless claims.

2026. g. 16. sept. 20:10 UTC

News

Amgen Inc has expanded its partnership with Veeva Systems, selecting Veeva Vault CRM to enhance global commercial execution, as shares trade slightly higher.

2026. g. 15. sept. 23:01 UTC

Amgen Inc shares are higher in after-market trading, reflecting a recovery from earlier losses despite being below its 20-day moving average and one-month range.

2026. g. 14. sept. 20:08 UTC

Social Media
News

Amgen Inc. shares rise after FDA approval for IMDELLTRA, reducing monitoring time for patients with extensive-stage small cell lung cancer. Positive sentiment noted on social media.

2026. g. 11. sept. 20:08 UTC

Macro Event

Amgen Inc shares are lower today following a drop in the Michigan Consumer Sentiment index, raising concerns over inflation and household budgets.

2026. g. 10. sept. 23:41 UTC

Amgen Inc. shares are higher in after-market trading, continuing a modest advance since Thursday's close, despite four consecutive lower daily closes.

2026. g. 8. sept. 20:03 UTC

News
Correlated Moves

Amgen Inc shares are lower today following Novartis' trial failure and a downgrade by BMO Capital to Market Perform, amid significant sell-off pressure.

2026. g. 4. sept. 23:02 UTC

Amgen Inc shares are lower in after-market hours, reflecting ongoing weakness. The stock is trading below its 20-day moving average and near a one-month low.

2026. g. 3. sept. 20:08 UTC

News

Erste Group Bank raised Amgen's FY2027 EPS estimate to $24.43, surpassing consensus. Shares are higher, continuing a trend of gains this week.

2026. g. 2. sept. 23:01 UTC

News

Amgen Inc. shares are lower in after-market hours despite announcing participation in the 2026 Wells Fargo Healthcare Conference on September 10, 2026.

2026. g. 1. sept. 23:06 UTC

Amgen Inc shares are higher in after-market trading, reflecting a notable rise since Tuesday's close and positioning the stock above its 20-day moving average.

2026. g. 31. aug. 23:01 UTC

Amgen Inc's shares are higher in after-market trading, rebounding from an earlier dip and reaching a notable high since Monday's close.

2026. g. 28. aug. 23:56 UTC

Amgen Inc shares are lower in after-market hours, continuing a trend of declines after four consecutive sessions of lower finishes. No specific news was identified.

2026. g. 27. aug. 23:02 UTC

Event

Amgen Inc. shares are higher in after-market trading following positive Phase 3 CROSSING trial results for TEZSPIRE in eosinophilic esophagitis patients.

2026. g. 26. aug. 23:51 UTC

Amgen Inc shares are lower in after-market hours following a volatile session. Broader inflation concerns were highlighted by the Commerce Department's latest price index.

2026. g. 25. aug. 23:16 UTC

Amgen Inc. shares were higher in after-market hours, supported by a decline in crude oil prices and decreasing treasury yields, indicating overall strength.

2026. g. 24. aug. 23:51 UTC

Amgen Inc. shares are lower in after-market trading with no specific news identified. The stock remains above its 20-day moving average.

2026. g. 21. aug. 20:06 UTC

Event

Amgen Inc. went ex-dividend today, distributing $2.52 per share, as shares trade higher since Thursday's close amid a strong broader market.

2026. g. 20. aug. 23:21 UTC

Amgen Inc. shares are lower in after-market trading, with no specific news identified. Rising U.S. Treasury yields contribute to broader market pressure.

2026. g. 19. aug. 22:56 UTC

Amgen Inc. shares declined slightly in after-hours trading, reflecting a minor decrease since Wednesday's close. The stock remains well above its 20-day moving average.

2026. g. 18. aug. 23:26 UTC

Amgen Inc shares are higher during after-market hours, maintaining a strong position above its 20-day moving average despite broader market pressures.

2026. g. 17. aug. 22:01 UTC

Amgen Inc shares are trading lower in after-market hours. Broader market volatility, influenced by rising crude oil prices, may be affecting investor sentiment.

2026. g. 14. aug. 19:46 UTC

News

Amgen shares are lower today despite Barclays raising the price target to $380, influenced by a decline in U.S. retail sales for July.

2026. g. 13. aug. 20:06 UTC

News

Amgen Inc reported second-quarter revenue of $10.05 billion, exceeding expectations. The company raised its full-year revenue and EPS guidance, contributing to shares moving higher.

2026. g. 12. aug. 19:56 UTC

News

Amgen Inc plans to open a new Science and Innovation Center in Hyderabad by 2027, enhancing its global R&D network. Shares are gaining today.

2026. g. 11. aug. 19:41 UTC

Social Media
News

Amgen Inc shares declined during Tuesday's session after peaking earlier. The stock remains above its 20-day moving average amid social media discussions on its long-term trajectory.

2026. g. 7. aug. 19:22 UTC

News

Amgen Inc shares are higher, supported by strong Q2 results and positive guidance revisions. The Biotechnology sub-sector is also advancing today.

2026. g. 6. aug. 19:56 UTC

Social Media
News

Amgen shares are lower today despite a price target increase from Bernstein. The stock reached a session high before retracing to midday lows.

2026. g. 5. aug. 19:52 UTC

Social Media
News

Amgen Inc. shares advanced following strong Q2 earnings and raised revenue guidance. Analysts from TD Cowen and Scotiabank maintained "Buy" ratings with high price targets.

Salīdzinājums

Cenas izmaiņa

Amgen Inc Prognoze

Cenas mērķis

By TipRanks

3.39% augšup

Prognoze 12 mēnešiem

Vidējais 398.727 USD  3.39%

Augstākais 460 USD

Zemākais 230 USD

Pamatojoties uz 24 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Amgen Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

24 ratings

9

Pirkt

13

Turēt

2

Pārdot

Noskaņojums

By Acuity

247 / 339 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.